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Abstract
Objectives:	The	aim	of	Working	Group	4	was	to	address	topics	related	to	biologic	
risks	and	complications	associated	with	implant	dentistry.	Focused	questions	on	(a)	
diagnosis	of	peri‐implantitis,	(b)	complications	associated	with	implants	in	augmented	
sites,	(c)	outcomes	following	treatment	of	peri‐implantitis,	and	(d)	implant	therapy	in	
geriatric	patients	and/or	patients	with	systemic	diseases	were	addressed.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes.
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1  | INTRODUC TION
The	 objectives	 of	 Group	 4	 of	 the	 6th	 ITI	 Consensus	 Conference	
were	to	provide	statements	and	recommendations	for	clinicians	and	
researchers	 relating	 to	 risks	 and	biologic	 complications	 in	 implant	
dentistry.	Four	systematic	reviews	formed	the	basis	for	discussion	
within	the	working	group	and	were	prepared	and	reviewed	prior	to	
the	consensus	conference.	The	systematic	reviews	were	discussed	
within	the	group,	and	minor	modifications,	as	required,	were	made	
to	 the	 manuscripts.	 The	 working	 group	 formed	 consensus	 state‐
ments	 and	 clinical	 recommendations	 which	 were	 then	 presented	
and	accepted	following	further	discussion	and	modifications	when	
required	by	the	plenary.	Recommendations	for	future	research	were	
also	prepared	by	 the	working	group.	The	 four	 systematic	 reviews	
are	listed	below.
The	 Diagnosis	 of	 Peri‐implantitis:	 A	 systematic	 review	 on	 the	
	predictive	 value	 of	 bleeding	 on	 probing	 (Hashim,	 Cionca,	
Combescure,	Mombelli,	2018).
Long‐term	biological	complications	of	dental	implants	placed	either	
in	pristine	or	in	augmented	sites:	A	systematic	review	and	meta‐
analysis	(Salvi,	Monje,	Tomasi,	2018).
Clinical	outcomes	of	peri‐implantitis	treatment	and	supportive	care:	
A	systematic	review	(Roccuzzo,	Layton,	Roccuzzo,	Heitz‐Mayfield,	
2018).
Effect	 of	 advanced	 age	 and/or	 systemic	 medical	 conditions	 on	
	dental	 implant	 survival:	 A	 systematic	 review	 and	meta‐analysis	
(Schimmel,	Srinivasan,	McKenna,	Müller,	2018).
2  | THE DIAGNOSIS OF PERI‐
IMPL ANTITIS:  THE PREDIC TIVE VALUE OF 
BLEEDING ON PROBING
2.1 | Preamble
Bleeding	 on	 probing	 has	 been	 proposed	 as	 one	 of	 the	 signs	 of	
mucositis	and/or	peri‐implantitis.	This	review	aimed	to	systematically	
evaluate	the	predictive	value	of	the	presence	or	absence	of	bleeding	
on	probing	(BOP)	alone	for	the	diagnosis	of	peri‐implantitis.
Thirty‐one	clinical	studies	reporting	on	the	prevalence	of	peri‐
implantitis,	 BOP	 and/or	 suppuration	 (SUP)	 after	 at	 least	 1	year	 of	
functional	 loading	 were	 selected.	 Meta‐analyses	 were	 conducted	
to	combine	 the	proportions	of	peri‐implantitis	 among	BOP	and/or	
SUP‐positive	 subjects	 and	 implants	 across	 studies	 up	 to	 18	years.	
Materials and methods:	Four	systematic	reviews	formed	the	basis	for	discussion	in	
Group	4.	Participants	developed	 statements	 and	 recommendations	determined	by	
group	consensus	based	on	the	findings	of	the	systematic	reviews.	These	were	then	
presented	and	accepted	following	further	discussion	and	modifications	as	required	by	
the	plenary.
Results:	 Bleeding	 on	 probing	 (BOP)	 alone	 is	 insufficient	 for	 the	 diagnosis	 of	 peri‐
implantitis.	 The	 positive	 predictive	 value	 of	 BOP	 alone	 for	 the	 diagnosis	 of	 peri‐
implantitis	varies	and	 is	dependent	on	the	prevalence	of	peri‐implantitis	within	 the	
population.	 For	 patients	with	 implants	 in	 augmented	 sites,	 the	 prevalence	 of	 peri‐
implantitis	 and	 implant	 loss	 is	 low	 over	 the	 medium	 to	 long	 term.	 Peri‐implantitis	
treatment	protocols	which	include	individualized	supportive	care	result	in	high	survival	
of	implants	after	5	years	with	about	three‐quarters	of	implants	still	present.	Advanced	
age	alone	is	not	a	contraindication	for	implant	therapy.	Implant	placement	in	patients	
with	cancer	receiving	high‐dose	antiresorptive	therapy	is	contraindicated	due	to	the	
associated	high	risk	for	complications.
Conclusions:	Diagnosis	of	peri‐implantitis	 requires	 the	presence	of	BOP	as	well	as	
progressive	bone	loss.	Prevalence	of	peri‐implantitis	for	implants	in	augmented	sites	
is	 low.	 Peri‐implantitis	 treatment	 should	 be	 followed	 by	 individualized	 supportive	
care.	 Implant	 therapy	 for	 geriatric	 patients	 is	 not	 contraindicated;	 however,	
comorbidities	and	autonomy	should	be	considered.
K E Y W O R D S
augmentation,	complication,	geriatric,	implant	survival,	peri‐implantitis,	supportive	care,	
systemic	conditions
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Subgroups	 were	 created	 and	 compared	 to	 investigate	 potential	
sources	of	heterogeneity.
For	 BOP‐positive	 patients,	 there	was	 a	 34%	 probability	 to	 be	
diagnosed	with	peri‐implantitis	(prediction	interval	10%	to	69%).	On	
average,	24%	of	 implants	which	presented	with	BOP	across	these	
studies	were	diagnosed	with	peri‐implantitis.	The	prediction	inter‐
val	ranged	from	7%	to	58%.	Thus,	we	can	assume	that	the	effect	size	
varied	across	populations.	Longer	observation	periods	were	signifi‐
cantly	associated	with	higher	proportions	of	peri‐implantitis	among	
BOP‐positive	implants,	reflecting	increasing	prevalence	with	time.
This	review	was	limited	in	its	analysis	by	the	heterogeneity	of	the	
populations	and	the	variable	definitions	of	peri‐implantitis.
2.2 | Consensus statements
2.2.1 | Consensus statement 1
The	positive	predictive	value	of	BOP	alone	for	the	diagnosis	of	peri‐
implantitis	for	each	implant	ranges	from	about	7%–58%,	depending	
on	the	prevalence	in	the	population.	This	means,	if	100	implants	pre‐
sent	with	BOP,	between	7	and	58	implants	may	have	peri‐implantitis.	
This	statement	is	based	upon	the	prediction	interval	of	6.9%–57.8%	
bounding	 the	weighted	mean	 (24.1%)	calculated	across	29	 studies	
identified	as	part	of	this	review.
2.2.2 | Consensus statement 2
The	positive	predictive	value	of	BOP	alone	increases	with	time	after	
loading.	This	probably	indicates	that	the	prevalence	of	peri‐implan‐
titis	 increases	with	time	after	 loading.	Shorter	observation	periods	
have	 lower	rates	of	peri‐implantitis,	while	 longer	observation	peri‐
ods	have	higher	rates	of	peri‐implantitis.	This	statement	is	based	on	
the	reduced	positive	predictive	value	of	BOP	identified	across	two	
studies	with	1‐	to	3‐year	mean	follow‐up	compared	with	27	studies	
with	more	than	a	3‐year	mean	follow‐up.
2.3 | Clinical recommendations
2.3.1 | What are the key criteria to diagnose the 
presence of peri‐implantitis?
BOP	alone	is	insufficient	for	the	diagnosis	of	peri‐implantitis.	The	diagno‐
sis	of	peri‐implantitis	requires	the	evaluation	of	inflammation/infection	
and	progressive	bone	loss	that	can	vary	between	implants	and	patients.
2.3.2 | What does the predictive value of a 
diagnostic test mean in clinical practice?
If	a	site	bleeds	after	probing,	there	is	a	chance	that	the	implant	may	
have	peri‐implantitis.	The	probability	that	this	is	the	case	is	called	the	
positive	predictive	value.	Clinicians	should	be	aware	that	the	posi‐
tive	predictive	value	of	a	diagnostic	test	may	vary	and	is	related	to	
the	prevalence	of	the	disease	within	the	specific	patient	population.	
In	specific	patient	populations	where	the	prevalence	of	peri‐implan‐
titis	may	be	increased,	the	predictive	value	may	be	higher	than	in	a	
general	patient	population.
2.4 | Recommendations for future research
•	 To	 investigate	 the	presence	of	BOP	as	 a	 risk	 factor	 for	 the	de‐
velopment	 of	 peri‐implantitis,	 specifically	 designed	 longitudinal	
studies	are	required.
•	 Biological	 conditions	of	human	BOP‐positive	and	negative	peri‐
implant	 tissues	 should	 be	 investigated,	 on	 a	 histological	 and	
molecular	 level,	 to	 better	 understand	 the	 underlying	 causes	 of	
bleeding	upon	probing.
•	 The	 documented	 relationship	 between	 probing	 force	 and	 fre‐
quency	of	BOP	at	healthy	teeth	suggests	that	tissue	trauma	due	to	
probing	with	an	inappropriate	force	may	occasionally	be	the	rea‐
son	for	bleeding	at	implants.	However,	recommendations	for	ideal	
probing	forces	at	implants	can	presently	not	be	made	due	to	lack	
of	evidence.	There	is	a	need	for	clinical	studies	determining	the	im‐
pact	of	various	factors	affecting	outcomes	of	peri‐implant	probing.
•	 Future	research	should	investigate	the	utility	of	different	assess‐
ments	of	bleeding,	such	as	a	bleeding	index,	rather	than	using	a	
dichotomous	evaluation	of	BOP.
•	 Research	should	explore	the	possibility	of	combining	other	diag‐
nostic	tools	with	BOP	to	increase	the	predictive	value.
3  | LONG ‐TERM BIOLOGIC AL 
COMPLIC ATIONS OF DENTAL IMPL ANTS 
PL ACED EITHER IN PRISTINE OR IN 
AUGMENTED SITES
3.1 | Preamble
Placement	 of	 dental	 implants	 in	 conjunction	 with	 augmentation	
procedures	 is	well	 documented	and	has	been	 shown	 to	yield	high	
predictability	in	terms	of	implant	survival	rates	and	volume	stability.	
However,	 a	 comparison	 between	 the	 long‐term	 prevalence	 of	
biological	 complications	 at	 implants	 placed	 in	 pristine	 sites	 (sites	
not	requiring	augmentation	prior	to	or	 in	conjunction	with	 implant	
placement)	versus	augmented	sites	is	lacking.
This	 systematic	 review	 investigated	 and	 compared	 the	 preva‐
lence	of	biological	complications	and	failure	(loss)	of	implants	placed	
in	pristine	versus	augmented	sites	after	a	mean	observation	period	of	
at	least	10	years.	The	following	focused	questions	were	addressed:
•	 In	 patients	with	 osseointegrated	 dental	 implants,	 are	 there	 dif‐
ferences	in	biological	complications	at	implants	placed	in	pristine	
versus	augmented	sites?
•	 In	 patients	with	 osseointegrated	 dental	 implants,	 are	 there	 dif‐
ferences	in	failure	rates	of	implants	placed	in	pristine	versus	aug‐
mented	sites?
354  |     HEITZ‐MAYFIELD ET AL.
The	systematic	 review	 included	8	 investigations	 (1	RCT,	1	case–
control	study,	1	cross‐sectional	study,	5	case	series).	The	mean	number	
of	 patients	 included	 across	 the	 studies	was	 56.9	 (range:	 15–96	 pa‐
tients),	while	the	mean	number	of	implants	was	113.5	(range:	15–153	
implants)	with	a	mean	follow‐up	of	11.1	years	(range:	10–15	years).
Various	augmentation	techniques	(e.g.,	lateral	and/or	vertical	aug‐
mentation,	augmentation	prior	to	or	at	the	time	of	implant	placement,	
and	 alveolar	 ridge	 preservation	 procedures	 prior	 to	 implant	 place‐
ment),	as	well	as	a	range	of	augmentation	materials	(e.g.,	autogenous	
bone	and	bone	substitutes)	and	barrier	membranes	(e.g.,	resorbable	
and	nonresorbable)	were	included	in	the	four	studies	reporting	on	im‐
plant	placement	in	augmented	sites.	All	included	studies	reported	that	
patients	were	enrolled	in	supportive	care	following	implant	therapy.
No	statistically	 significant	differences	were	observed	between	
implants	placed	in	pristine	versus	augmented	sites	for	any	outcome	
variable	both	at	patient	and	implant	level.	High	heterogeneity	con‐
cerning	patient	sampling,	case	definitions	of	biological	complications	
and	eligibility	criteria	were	observed.
Sufficient	data	were	available	to	perform	meta‐analyses	for	the	
primary	outcome	(biological	complications)	and	secondary	outcome	
(implant	failure).
3.2 | Consensus statements
3.2.1 | Consensus statement 1
There	is	evidence	that	patients	receiving	implants	in	augmented	sites	
may	display	a	comparable	prevalence	of	peri‐implant	mucositis	com‐
pared	with	patients	receiving	implants	in	pristine	sites.	Patients	with	
implants	 placed	 in	 pristine	 sites	 have	 a	 prevalence	 of	 peri‐implant	
mucositis	of	22.4%	(95%	CI:	6%–38%)	compared	with	a	prevalence	of	
19.6%	(95%	CI:	0%–40%)	for	patients	with	implants	in	augmented	sites.
This	statement	 is	based	on	1	RCT,	1	case–control	study,	and	4	
case	series	studies.
3.2.2 | Consensus statement 2
There	is	evidence	that	the	long‐term	prevalence	of	peri‐implantitis	
in	patients	with	implants	in	pristine	sites	and	augmented	sites	is	low.	
The	prevalence	of	peri‐implantitis	in	patients	with	implants	in	aug‐
mented	sites	is	more	variable	and	less	predictable	compared	with	the	
prevalence	in	patients	with	implants	in	pristine	sites.	The	weighted	
mean	prevalence	of	peri‐implantitis	in	patients	with	implants	in	aug‐
mented	sites	was	17.8%	 (95%	CI:	0%–37%)	compared	with	 that	of	
10.3%	(95%	CI:	4%–17%)	in	patients	with	implants	in	pristine	sites.
This	statement	 is	based	on	1	RCT,	1	case–control	study,	and	4	
case	series	studies.
3.2.3 | Consensus statement 3
There	 is	 some	 evidence	 that	 the	 long‐term	 prevalence	 of	 implant	
failure	(loss)	in	patients	with	implants	in	pristine	sites	and	augmented	
sites	is	low.
The	 weighted	mean	 prevalence	 of	 implant	 failure	 (loss)	 in	 pa‐
tients	with	implants	in	augmented	sites	was	3.6%	(95%	CI:	0%–8%)	
compared	with	 that	of	2.5%	 (95%	CI:	1%–4%)	 in	patients	with	 im‐
plants	in	pristine	sites.
This	statement	 is	based	on	1	RCT,	1	case–control	study,	and	4	
case	series	studies.
3.2.4 | Consensus statement 4
In	 patients	with	 a	 history	 of	 treated	periodontitis	 (moderate	 and	
severe)	receiving	implant	therapy	in	pristine	sites,	compliance	with	
regular	supportive	care	yields	lower	long‐term	implant	failure	(loss)	
compared	 with	 patients	 not	 complying	 with	 regular	 supportive	
care.
This	statement	is	based	on	1	study.
3.2.5 | Consensus statement 5
There	is	limited	evidence	concerning	the	effect	of	regular	supportive	
care	in	patients	with	a	history	of	treated	periodontitis	receiving	im‐
plants	in	augmented	sites.
This	statement	is	based	on	1	study.
3.3 | Clinical recommendations
3.3.1 | For the long‐term monitoring of biological 
complications, at what time points should implants 
placed in augmented sites be assessed? 
The	time	of	completion	of	the	implant‐supported	prosthesis	should	
be	used	as	a	baseline	for	assessment.	Similar	to	 implants	placed	in	
pristine	sites,	implants	placed	in	augmented	sites	should	have	time‐
points	for	subsequent	assessments	determined	by	the	individual	risk	
profile	of	the	patient.
3.3.2 | Do patients with implants in augmented sites 
require specific supportive care?
Patients	with	implants	in	augmented	and	pristine	sites	should	both	
be	enrolled	in	regular	supportive	care.	Special	consideration	should	
be	given	to	periodontally	susceptible	patients	with	implants	placed	
in	augmented	sites.
3.4 | Recommendations for future research
•	 The	 influence	of	 factors	 including	defect	morphology,	 augmen‐
tation	 technique,	 and	 augmentation	materials	 (bone	 substitutes	
and	 barrier	 membranes)	 on	 the	 occurrence	 of	 biologic	 compli‐
cations	should	be	 investigated	 in	observational	and	randomized	
controlled	trials.
•	 The	impact	of	implant	placement	in	augmented	versus	pristine	sites	
on	the	development	of	biological	complications	and	implant	failure	
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(loss)	 needs	 to	 be	 investigated	 in	 randomized	 controlled	 clinical	
trials.
•	 The	 impact	of	compliance	with	supportive	care	 in	patients	with	
implants	placed	in	augmented	sites	on	the	development	of	long‐
term	biological	complications	and	 implant	 failure	 (loss)	needs	to	
be	 investigated	 in	well‐designed	observational	 studies	 and	 ran‐
domized	controlled	clinical	trials.
4  | OUTCOMES OF PERI‐ IMPL ANTITIS 
TRE ATMENT FOLLOWED BY SUPPORTIVE 
C ARE
4.1 | Preamble
There	is	a	need	to	establish	effective	treatment	protocols	for	the	
management	 of	 peri‐implantitis	 to	 achieve	 stable	 long‐term	 out‐
comes.	 The	 5th	 ITI	 Consensus	 found	 successful	 12‐month	 out‐
comes	 following	 peri‐implantitis	 treatment	 could	 be	 achieved	 in	
a	 limited	 number	 of	 studies	 (Heitz‐Mayfield,	Needleman,	 Salvi	&	
Pjetursson,	2014).	In	these	studies,	although	favorable	short‐term	
peri‐implantitis	treatment	outcomes	were	reported	in	the	majority	
of	patients	and	implants,	nonresolution	of	peri‐implantitis,	disease	
recurrence,	progression	of	bone	loss	and	implant	loss	were	also	re‐
ported.	The	majority	of	 studies	 reported	 treatment	outcomes	 in‐
consistently.	Few	studies	reported	medium	to	long‐term	outcomes.	
Furthermore,	 the	 effect	 of	 supportive	 care	 (supportive	 peri‐im‐
plant/periodontal	 therapy,	 SPT)	 on	 treatment	 outcomes	was	 not	
addressed.
Therefore,	 the	 aim	 of	 this	 systematic	 review	was	 to	 evaluate	
the	 clinical	 outcomes	 for	patients	with	 implants	 treated	 for	peri‐
implantitis	who	subsequently	received	supportive	care	for	at	least	
3 years.
The	 primary	 outcome	 was	 survival	 (both	 at	 implant	 and	 pa‐
tient	 level),	 defined	 as	 the	 presence	 of	 the	 implant,	 regardless	 of	
the	 health	 of	 the	 surrounding	 tissues.	 Secondary	 outcomes	were	
implant	 success	 and	 peri‐implantitis	 recurrence,	 if	 defined	 by	 the	
authors.
The	results	of	this	systematic	review	are	based	on	18	studies,	of	
which	13	could	be	used	for	quantitative	assessments.	On	average,	
26	patients	(median,	IQR	21–32)	with	36	implants	(median,	IQR	26–
45)	were	included	in	those	13	studies.	Sufficient	data	were	available	
to	perform	meta‐analyses	of	the	primary	outcome.
4.2 | Consensus statements
4.2.1 | Consensus statement 1
In	patients	successfully	treated	for	peri‐implantitis,	an	individualized	
supportive	care	program,	including	professional	and	self‐performed	
biofilm	removal	at	implants	and	teeth,	is	associated	with	positive	me‐
dium‐	to	long‐term	outcomes.
This	statement	is	based	on	the	results	of	18	studies.
4.2.2 | Consensus statement 2
Under	 current	 peri‐implantitis	 treatment	 protocols,	 which	 include	
supportive	care,	about	three‐quarters	of	 implants	treated	for	peri‐
implantitis	may	still	be	present	after	5	years.	These	outcomes	might	
be	affected	by	patient,	implant‐,	prosthesis‐,	and	treatment‐related	
factors.
This	statement	is	based	on	13	studies,	presenting	an	estimated	
cumulative	implant	survival	of	76%–100%	across	4	studies	at	5	years	
and	of	70%–99%	across	2	studies	at	7	years.
4.2.3 | Consensus statement 3
Although	 limited,	 there	 is	 evidence	 that	 implant	 surface	 can	 affect	
the	 medium‐	 to	 long‐term	 stability	 of	 peri‐implantitis	 treatment	
outcomes.
This	statement	is	based	on	the	findings	of	two	studies.	One	study	
found	 reduced	 success	 outcomes	 of	 implants	 with	 TPS	 (titanium	
plasma	 sprayed)	 compared	 with	 SLA	 (sandblasted	 large‐grit	 acid‐
etched)	surfaces	over	7	years.	One	study	found	reduced	outcomes	
of	moderately	rough	compared	with	turned/minimally	rough	implant	
surfaces	over	3	years.
4.2.4 | Consensus statement 4
Despite	 receiving	 regular	 supportive	 care,	 certain	 patients	 may	
require	 retreatment,	 adjunctive	 therapies,	 and/or	 implant	 removal	
due	to	disease	progression	or	recurrence.
This	statement	is	based	on	2	studies	that	reported	peri‐implan‐
titis	recurrence	and	5	studies	that	reported	on	treatment	success.
4.3 | Clinical recommendations
4.3.1 | What definition of peri‐implantitis treatment 
success is practical in clinical practice?
Peri‐implantitis	treatment	success	 is	defined	as	stable	peri‐implant	
bone	levels,	absence	of	probing	depths	>5	mm,	and	no	bleeding	or	
suppuration	on	probing.
Success	in	clinical	practice,	however,	may	be	defined	as	the	ab‐
sence	of	progression	of	 the	disease,	 regardless	of	whether	clinical	
parameters	adhere	to	the	above	strict	success	criteria.
In	addition,	patients	may	also	 require	 that	 their	 implant	 recon‐
structions	are	aesthetic,	comfortable,	and	easy	to	clean	in	order	to	
consider	the	treatment	a	success.
4.3.2 | What clinical signs indicate that there is 
recurrence of peri‐implantitis?
After	having	achieved	resolution	of	peri‐implantitis,	the	presence	of	
bleeding	and/or	suppuration	on	probing	together	with	an	increase	in	
probing	depth	may	indicate	recurrence	of	disease.	A	radiograph	may	
be	indicated	if	a	diagnosis	remains	unclear.
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4.3.3 | What peri‐implantitis treatment protocols could 
be considered appropriate to use in daily clinical practice?
Certain	steps	should	be	followed	during	the	active	treatment	of	peri‐
implantitis	as	outlined	in	the	5th	ITI	Consensus	Statements	(Heitz‐
Mayfield	et	al.,	2014).	These	steps	include:
1. Thorough	 assessment	 and	 diagnosis.
2. Control	 of	 modifiable	 local	 and	 systemic	 risk	 factors	 for	
peri‐implantitis.
3. Nonsurgical	debridement.
4. Early	 reassessment	 of	 peri‐implant	 health,	 generally	 within	
1‐2	months
5. Surgical	access	if	resolution	has	not	been	achieved,	including:
•	 Open	flap	debridement
•	 Thorough	surface	decontamination	of	the	implant	and	associ‐
ated	prosthetic	components.
•	 Option	of	regenerative/reconstructive	or	resective	approaches
•	 Appropriate	postoperative	anti‐infective	therapy
6. Supportive	care	tailored	to	the	patient	risk	profile,	most	likely	3–6	
monthly.
4.3.4 | What supportive care protocols can be 
considered appropriate to use in daily clinical practice?
Various	supportive	care	protocols	have	been	proposed.	It	is	recom‐
mended	to	provide	individualized	supportive	care	according	to	the	
patient’s	needs	and	risk	profile.
Supportive	care	should	include	oral	hygiene	measures,	biofilm	re‐
moval,	monitoring	oral	health,	and	reduction	in	modifiable	risks	related	
to	peri‐implantitis.	Every	effort	should	be	made	to	motivate	the	patient	
and	facilitate	their	ability	to	maintain	plaque	control	both	at	implants	
and	teeth,	aiming	for	a	low	full	mouth	plaque	score	(FMPS	<20%).
4.3.5 | Are there any implant variables that 
could influence long‐term outcomes of an implant 
successfully treated for peri‐implantitis?
Clinicians	 should	 be	 aware	 that	 implant	 surface	 characteristics	
may	 have	 an	 impact	 on	 treatment	 success.	 Other	 implant	 and	
prosthetic	variables	may	also	impact	on	treatment	success,	requiring	
modification	of	the	supportive	care	program.
4.4 | Recommendations for future research
•	 Studies	 should	 use	 consistent	 definitions	 for	 peri‐implantitis	
treatment	success,	survival,	nonresolution,	and	recurrence.
•	 Studies	to	evaluate	different	protocols	for	supportive	care	follow‐
ing	peri‐implantitis	treatment	are	required.
•	 Studies	to	evaluate	the	efficacy	of	different	methods	of	profes‐
sional	biofilm	removal,	self‐performed	oral	hygiene,	and	support‐
ive	care	intervals	are	required.
•	 Studies	to	evaluate	the	influence	of	patient‐,	 implant‐,	and	pros‐
thesis‐related	factors	on	supportive	care	protocol	choice,	follow‐
ing	peri‐implantitis	treatment,	are	required.
•	 Studies	to	evaluate	the	influence	of	patient‐,	implant‐,	and	pros‐
thesis‐related	 factors	 on	 the	 long‐term	 outcomes	 of	 patients	
in	 supportive	 care	 following	 peri‐implantitis	 treatment	 are	
required.
•	 Health	 economic	 and	 cost–utility	 analyses	 for	 supportive	 care	
programs	following	peri‐implantitis	treatment	are	required.
•	 Patient‐reported	outcomes	(e.g.,	oral	health‐related	quality	of	life,	
patient	preference,	and	aesthetics)	for	peri‐implantitis	treatment	
protocols	that	include	supportive	care	should	be	evaluated.
5  | EFFEC T OF ADVANCED AGE , AND/
OR SYSTEMIC MEDIC AL CONDITIONS ON 
DENTAL IMPL ANT SURVIVAL
5.1 | Preamble
Today’s	 aged	 generation	 presents	 new	 challenges	 in	 the	 field	 of	
implant	dentistry.	Implant	patients	of	advanced	age	often	present	with	
functional	 dependency,	 systemic	medical	 conditions	 (comorbidities),	
and	 frailty.	 In	 addition,	 the	 aging	 of	 the	 immune	 system,	 termed	
immunosenescence,	may	 result	 in	a	compromised	host	defense	 to	a	
bacterial	 challenge	 at	 dental	 implants	 which	 adversely	 affects	 peri‐
implant	health.
Furthermore,	the	presence	of	systemic	conditions	and	treatment	
of	these	conditions	may	present	a	risk	for	implant	placement,	main‐
tenance	of	peri‐implant	health,	and	ultimately	implant	survival.	The	
most	common	systemic	conditions	in	geriatric	patients,	as	reported	
by	 the	World	Health	Organization	 (WHO)	 in	2015,	 are	 cardiovas‐
cular	disease	(CVD),	cancer,	respiratory	diseases,	diabetes	mellitus,	
liver	cirrhosis,	osteoarthritis,	and	conditions	that	involve	neurocog‐
nitive	impairment.
This	systematic	review	addressed	the	focused	questions:	“In	pa‐
tients	undergoing	dental	 implant	therapy,	what	is	the	effect	of	ad‐
vanced	age	(≥75	years)	and/or	common	systemic	medical	conditions	
on	implant	survival	and	biologic	complication	rates?”
The	 systematic	 review	 included	 evidence	 from	60	 studies,	 of	
which	7	provided	sufficient	information	to	perform	meta‐analyses	
based	 on	 the	 primary	 outcome	 ‐	 implant	 survival	 in	 geriatric	 pa‐
tients	 (≥75	years).	One‐year	 implant	survival	was	based	on	7	pro‐
spective	 studies	with	 a	mean	of	 35	 implants,	 and	5‐year	 implant	
survival	 was	 based	 on	 3	 prospective	 studies	 with	 a	 mean	 of	 25	
implants.
The	 remaining	 53	 studies	 reported	 on	 implant	 survival	 in	 pa‐
tients	with	the	most	common	systemic	medical	conditions	and	their	
respective	treatments	(CVD,	radiation	therapy,	antiresorptive	ther‐
apy	(ART),	hyposalivation/dry	mouth,	diabetes	mellitus,	and	neuro‐
cognitive	impairment),	irrespective	of	the	patients’	age.
Annual	mean	peri‐implant	marginal	bone	 loss	 (PI‐MBL)	was	re‐
ported	in	seven	studies.
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5.2 | Consensus statements
5.2.1 | Consensus statement 1
Advanced	age	alone	(≥75	years)	is	not	a	contraindication	for	implant	
therapy.
This	statement	is	based	on	7	prospective	studies.
5.2.2 | Consensus statement 2
Peri‐implant	marginal	bone	loss	(PI‐MBL)	in	geriatric	patients	is	low	
and	similar	to	other	age	groups	after	one	to	5‐year	follow‐up.
This	statement	is	based	on	7	prospective	studies,	where	PI‐MBL	
was	calculated	to	be	between	0.1	mm	and	0.2	mm	annually	over	a	
recall	 period	of	up	 to	5	years	 and	0.51	mm	 for	 the	 first‐year	 after	
loading.
5.2.3 | Consensus statement 3
Few	studies	 in	 implantology	focus	on	geriatric	patients	 (≥75	years)	
and	systemic	medical	conditions	(comorbidities)	common	in	old	age.
5.2.4 | Consensus statement 4
Evidence	suggests,	 that	 in	patients	with	cardiovascular	disease	
(CVD),	 including	 ischemic	 heart	 disease,	 stroke,	 and	 hyperten‐
sive	heart	disease,	implant	survival	is	similar	to	patients	without	
CVD.
This	statement	 is	based	on	one	cross‐sectional	and	one	cohort	
study.	The	calculated	implant	survival	ranges	from	98%	to	100%	in	
patients	with	CVD.
5.2.5 | Consensus statement 5
In	patients	with	head	and	neck	cancer,	implant	survival	may	be	nega‐
tively	 affected	 by	 radiotherapy.	 Treatment	 protocols	 for	 implant	
placement	in	irradiated	patients	have	been	developed.
In	oncology	patients	receiving	high‐dose	antiresorptive	therapy	
(ART),	implant	surgery	carries	a	high	risk	for	postoperative	complica‐
tions	and	is	contraindicated.	High‐dose	ART	is	described	as	any	ART	
treatment	administered	in	oncology	patients	with	bone	metastases.	
In	oncology	patients,	the	long‐term	effects	of	chemotherapy	on	oral	
tissues	have	not	been	investigated.
This	 statement	 is	based	on	16	 studies	on	 radiotherapy	and	on	
two	studies	on	ART	focussing	on	the	development	of	medication‐re‐
lated	osteonecrosis	of	the	jaw	(MRONJ).	No	studies	reported	on	the	
effects	of	chemotherapy	alone.
5.2.6 | Consensus statement 6
Treatment	 for	 cancer	 is	 commonly	associated	with	hyposalivation.	
Hyposalivation	is	also	commonly	associated	with	polypharmacy	and	
Sjögren’s	syndrome.	While	implant	survival	in	patients	with	Sjögren’s	
syndrome	is	reported	to	be	very	high,	the	effect	of	cancer	treatment	
and	polypharmacy	has	not	been	reported.
This	statement	is	based	on	5	studies.
5.2.7 | Consensus statement 7
In	adult	patients	with	diabetes	mellitus	type	II,	high	implant	survival	
rates	may	be	achieved.
This	statement	is	based	on	7	studies	for	patients	in	the	mean	age	
range	of	49.5–64	years.
5.2.8 | Consensus statement 8
Patients	with	conditions	 involving	neurocognitive	 impairment	 (uni‐
polar	 depression,	 Alzheimer’s	 disease	 and	 other	 dementias,	 and	
Parkinson’s	disease)	can	experience	high	implant	survival	rates.
This	statement	 is	based	on	7	studies,	 including	4	case	reports.	
The	mean	age	ranged	from	44	to	83	years	and	an	observation	period	
of	3–72	months.
5.2.9 | Consensus statement 9
No	 evidence	 was	 identified	 related	 to	 other	 diseases	 that	 are	
common	among	 the	elderly	 (WHO,	2015)	 such	as	 liver	 cirrhosis,	
respiratory	 diseases	 and	 osteoarthritis,	 in	 relation	 to	 implant	
therapy.
5.3 | Clinical recommendations
5.3.1 | Is there an upper age limit for 
implant therapy?
In	geriatric	patients,	implant	therapy	may	be	considered	irrespective	
of	age.	Implant	and	prosthesis	maintenance	must	be	assured	by	the	
patient	and/or	care	provider.
5.3.2 | Which common comorbidities comprise 
contraindications for implant placement?
High‐dose	 antiresorptive	 therapy	 (ART)	 poses	 a	 serious	 risk	 for	
postoperative	 complications	 and	 is	 a	 contraindication	 for	 implant	
surgery.	 If	 treated	 at	 all,	 these	 patients	 should	 be	 managed	 in	 a	
specialist	setting.
5.3.3 | Which common comorbidities comprise risks 
for implant placement?
Comorbidities	 such	 as	 cancer,	 diabetes	 mellitus,	 and	 conditions	
involving	 neurocognitive	 impairment	 may	 carry	 risks	 for	 implant	
therapy.	 An	 individual	 risk	 assessment	 is	 necessary	 before	
considering	 implant	 surgery	 for	 these	 patients.	 Implant	 patients	
with	comorbidities	should	be	managed	in	close	collaboration	with	a	
supervising	physician	with	regular	follow‐up.
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In	patients	with	diabetes	mellitus,	oral	hygiene	should	be	closely	
monitored	along	with	glycemic	control	and	associated	comorbidities	
of	the	disease.
5.3.4 | Which information must be taken into 
account when planning implant therapy for geriatric 
patients with common systemic diseases?
While	there	is	no	evidence	to	preclude	geriatric	patients	(≥75	years)	
from	 implant	 therapy	 it	 is	 advisable	 to	 perform	 an	 individual	 risk	
assessment	 for	 patients	 with	 comorbidities.	 In	 geriatric	 patients,	
a	 holistic	 approach	 is	 required	 which	 should	 include	 assessment	
of	 functional	dependency	 in	addition	 to	 related	 limitations	 for	 the	
use	of	implant‐supported	prostheses	and	the	ability	to	perform	oral	
hygiene	 measures.	 The	 progression	 of	 existing	 systemic	 disease	
and	dependency	as	well	as	the	patient’s	 life	expectancy	should	be	
considered	in	the	context	of	availability	of	competent	care.
5.3.5 | What are the risks and benefits associated with 
implant therapy in geriatric patients and patients suffering 
from the most common diseases in geriatric patients?
Implants	may	be	considered	in	elderly	and	medically	compromised	
patients	when	they	can	provide	substantial	functional	and	psycho‐
social	benefits,	which	must	outweigh	the	associated	risks,	cost,	and	
burden	of	treatment.
5.3.6 | What public health issues are important to 
consider for successful implant therapy in geriatric 
patients?
When	older	patients	lose	independence,	the	availability	of	trained	manpower	
in	 the	caring	professions	 is	a	potential	 limiting	 factor	 for	 implant	 therapy.	
Opportunities	for	education	and	additional	training	focused	on	oral	health	
should	be	provided	for	those	involved	in	caring	for	dependent	persons.
5.4 | Recommendations for future research
•	 Future	research	should	focus	on	evaluation	of	clinical	outcomes	
of	implant	therapy	in	patients	with	advanced	age	and	comorbid‐
ities	with	detailed	and	standardized	reporting	of	systemic	condi‐
tions	and	related	therapies.
•	 Studies	 to	 address	 predictors	 for	 successful	 implant	 therapy	 in	
geriatric	patients	during	patient	selection,	prior	 to	 implant	 ther‐
apy	are	required.
•	 Future	 research	 is	 required	 to	 study	 the	mechanisms	 of	 immu‐
nosenescence	and	its	effect	on	peri‐implant	health	and	osseointe‐
gration	in	geriatric	patients.
•	 Future	research	is	required	to	evaluate	optimal	implant–prosthe‐
sis	design	to	facilitate	oral	hygiene	measures	for	maintenance	of	
peri‐implant	health	in	geriatric	patients.
•	 Evaluation	of	access	to	quality	oral	health	care	for	immobile	and	
dependent	persons	is	required	to	develop	health	policies	for	the	
provision	of	a	minimum	standard	of	oral	care	in	aged	care.
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